1
|
Sala E, Vived C, Luna J, Saavedra-Ávila NA, Sengupta U, Castaño AR, Villar-Pazos S, Haba L, Verdaguer J, Ropero AB, Stratmann T, Pizarro J, Vázquez-Carrera M, Nadal A, Lahti JM, Mora C. CDK11 Promotes Cytokine-Induced Apoptosis in Pancreatic Beta Cells Independently of Glucose Concentration and Is Regulated by Inflammation in the NOD Mouse Model. Front Immunol 2021; 12:634797. [PMID: 33664748 PMCID: PMC7923961 DOI: 10.3389/fimmu.2021.634797] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2020] [Accepted: 01/07/2021] [Indexed: 11/13/2022] Open
Abstract
Background Pancreatic islets are exposed to strong pro-apoptotic stimuli: inflammation and hyperglycemia, during the progression of the autoimmune diabetes (T1D). We found that the Cdk11(Cyclin Dependent Kinase 11) is downregulated by inflammation in the T1D prone NOD (non-obese diabetic) mouse model. The aim of this study is to determine the role of CDK11 in the pathogenesis of T1D and to assess the hierarchical relationship between CDK11 and Cyclin D3 in beta cell viability, since Cyclin D3, a natural ligand for CDK11, promotes beta cell viability and fitness in front of glucose. Methods We studied T1D pathogenesis in NOD mice hemideficient for CDK11 (N-HTZ), and, in N-HTZ deficient for Cyclin D3 (K11HTZ-D3KO), in comparison to their respective controls (N-WT and K11WT-D3KO). Moreover, we exposed pancreatic islets to either pro-inflammatory cytokines in the presence of increasing glucose concentrations, or Thapsigargin, an Endoplasmic Reticulum (ER)-stress inducing agent, and assessed apoptotic events. The expression of key ER-stress markers (Chop, Atf4 and Bip) was also determined. Results N-HTZ mice were significantly protected against T1D, and NS-HTZ pancreatic islets exhibited an impaired sensitivity to cytokine-induced apoptosis, regardless of glucose concentration. However, thapsigargin-induced apoptosis was not altered. Furthermore, CDK11 hemideficiency did not attenuate the exacerbation of T1D caused by Cyclin D3 deficiency. Conclusions This study is the first to report that CDK11 is repressed in T1D as a protection mechanism against inflammation-induced apoptosis and suggests that CDK11 lies upstream Cyclin D3 signaling. We unveil the CDK11/Cyclin D3 tandem as a new potential intervention target in T1D.
Collapse
Affiliation(s)
- Ester Sala
- Immunology Unit, Department of Experimental Medicine, Faculty of Medicine, University of Lleida, Lleida, Spain
- Institut de Recerca Biomèdica Lleida (IRB-LLeida), Lleida, Spain
| | - Celia Vived
- Immunology Unit, Department of Experimental Medicine, Faculty of Medicine, University of Lleida, Lleida, Spain
- Institut de Recerca Biomèdica Lleida (IRB-LLeida), Lleida, Spain
| | - Júlia Luna
- Immunology Unit, Department of Experimental Medicine, Faculty of Medicine, University of Lleida, Lleida, Spain
- Institut de Recerca Biomèdica Lleida (IRB-LLeida), Lleida, Spain
| | - Noemí Alejandra Saavedra-Ávila
- Immunology Unit, Department of Experimental Medicine, Faculty of Medicine, University of Lleida, Lleida, Spain
- Institut de Recerca Biomèdica Lleida (IRB-LLeida), Lleida, Spain
| | - Upasana Sengupta
- Immunology Unit, Department of Experimental Medicine, Faculty of Medicine, University of Lleida, Lleida, Spain
- Institut de Recerca Biomèdica Lleida (IRB-LLeida), Lleida, Spain
| | - A. Raúl Castaño
- Departament of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona, Barcelona, Spain
| | - Sabrina Villar-Pazos
- Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche, IDiBE, Universidad Miguel Hernandez, Elche, Spain
- Department of Tumor Cell Biology, St. Jude Children’s Research Hospital, Memphis, TN, United States
| | - Laura Haba
- Experimental Diabetes Laboratory, Institute for Biomedical Research August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Joan Verdaguer
- Immunology Unit, Department of Experimental Medicine, Faculty of Medicine, University of Lleida, Lleida, Spain
- Institut de Recerca Biomèdica Lleida (IRB-LLeida), Lleida, Spain
| | - Ana B. Ropero
- Instituto de Bioingeniería, Universidad Miguel Hernández, Elche, Spain
| | - Thomas Stratmann
- Department of Cell Biology, Physiology and Immunology, Faculty of Biology, University of Barcelona, Barcelona, Spain
| | - Javier Pizarro
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences and Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain
- Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM)—Instituto de Salud Carlos III, Madrid, Spain
- Pediatric Research Institute, Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain
| | - Manuel Vázquez-Carrera
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences and Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain
- Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM)—Instituto de Salud Carlos III, Madrid, Spain
- Pediatric Research Institute, Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain
| | - Angel Nadal
- Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche, IDiBE, Universidad Miguel Hernandez, Elche, Spain
- Diabetes and Associated Metabolic Disorders CIBERDEM, Universidad Miguel Hernández de Elche, Elche, Spain
| | - Jill M. Lahti
- Department of Tumor Cell Biology, St. Jude Children’s Research Hospital, Memphis, TN, United States
| | - Conchi Mora
- Immunology Unit, Department of Experimental Medicine, Faculty of Medicine, University of Lleida, Lleida, Spain
- Institut de Recerca Biomèdica Lleida (IRB-LLeida), Lleida, Spain
| |
Collapse
|
3
|
Zhou Y, Shen JK, Hornicek FJ, Kan Q, Duan Z. The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer. Oncotarget 2016; 7:40846-40859. [PMID: 27049727 PMCID: PMC5130049 DOI: 10.18632/oncotarget.8519] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2016] [Accepted: 03/28/2016] [Indexed: 12/17/2022] Open
Abstract
Overexpression and/or hyperactivation of cyclin-dependent kinases (CDKs) are common features of most cancer types. CDKs have been shown to play important roles in tumor cell proliferation and growth by controlling cell cycle, transcription, and RNA splicing. CDK4/6 inhibitor palbociclib has been recently approved by the FDA for the treatment of breast cancer. CDK11 is a serine/threonine protein kinase in the CDK family and recent studies have shown that CDK11 also plays critical roles in cancer cell growth and proliferation. A variety of genetic and epigenetic events may cause universal overexpression of CDK11 in human cancers. Inhibition of CDK11 has been shown to lead to cancer cell death and apoptosis. Significant evidence has suggested that CDK11 may be a novel and promising therapeutic target for the treatment of cancers. This review will focus on the emerging roles of CDK11 in human cancers, and provide a proof-of-principle for continued efforts toward targeting CDK11 for effective cancer treatment.
Collapse
Affiliation(s)
- Yubing Zhou
- Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China
- Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA, United States of America
| | - Jacson K. Shen
- Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA, United States of America
| | - Francis J. Hornicek
- Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA, United States of America
| | - Quancheng Kan
- Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China
| | - Zhenfeng Duan
- Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China
- Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA, United States of America
| |
Collapse
|
4
|
Nagarajan P, Parikh N, Garrett-Sinha LA, Sinha S. Ets1 induces dysplastic changes when expressed in terminally-differentiating squamous epidermal cells. PLoS One 2009; 4:e4179. [PMID: 19142229 PMCID: PMC2615206 DOI: 10.1371/journal.pone.0004179] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2008] [Accepted: 11/28/2008] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Ets1 is an oncogene that functions as a transcription factor and regulates the activity of many genes potentially important for tumor initiation and progression. Interestingly, the Ets1 oncogene is over-expressed in many human squamous cell cancers and over-expression is highly correlated with invasion and metastasis. Thus, Ets1 is believed to mainly play a role in later stages of the oncogenic process, but not early events. METHODOLOGY/PRINCIPAL FINDINGS To better define the role of Ets1 in squamous cell carcinogenesis, we generated a transgenic mouse model in which expression of the Ets1 oncogene could be temporally and spatially regulated. Upon Ets1 induction in differentiating cells of stratified squamous epithelium, these mice exhibited dramatic changes in epithelial organization including increased proliferation and blocked terminal differentiation. The phenotype was completely reversed when Ets1 expression was suppressed. In mice where Ets1 expression was re-induced at a later age, the phenotype was more localized and the lesions that developed were more invasive. Many potential Ets1 targets were upregulated in the skin of these mice with the most dramatic being the metalloprotease MMP13, which we demonstrate to be a direct transcriptional target of Ets1. CONCLUSIONS/SIGNIFICANCE Collectively, our data reveal that upregulation of Ets1 can be an early event that promotes pre-neoplastic changes in epidermal tissues via its regulation of key genes driving growth and invasion. Thus, the Ets1 oncogene may be important for oncogenic processes in both early and late stages of tumor development.
Collapse
Affiliation(s)
- Priyadharsini Nagarajan
- Department of Biochemistry, State University of New York at Buffalo, Center for Excellence in Bioinformatics and Life Sciences, Buffalo, New York, United States of America
| | - Neha Parikh
- Department of Biochemistry, State University of New York at Buffalo, Center for Excellence in Bioinformatics and Life Sciences, Buffalo, New York, United States of America
| | - Lee Ann Garrett-Sinha
- Department of Biochemistry, State University of New York at Buffalo, Center for Excellence in Bioinformatics and Life Sciences, Buffalo, New York, United States of America
- * E-mail: (LAG-S); (SS)
| | - Satrajit Sinha
- Department of Biochemistry, State University of New York at Buffalo, Center for Excellence in Bioinformatics and Life Sciences, Buffalo, New York, United States of America
- * E-mail: (LAG-S); (SS)
| |
Collapse
|
5
|
De Bleser P, Hooghe B, Vlieghe D, van Roy F. A distance difference matrix approach to identifying transcription factors that regulate differential gene expression. Genome Biol 2007; 8:R83. [PMID: 17504544 PMCID: PMC1929144 DOI: 10.1186/gb-2007-8-5-r83] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2006] [Revised: 03/30/2007] [Accepted: 05/16/2007] [Indexed: 01/10/2023] Open
Abstract
We introduce a method that considers target genes of a transcription factor, and searches for transcription factor binding sites (TFBSs) of secondary factors responsible for differential responses among these targets. Based on the distance difference matrix concept, the method simultaneously integrates statistical overrepresentation and co-occurrence of TFBSs. Our approach is validated on datasets of differentially regulated human genes and is shown to be highly effective in detecting TFBSs responsible for the observed differential gene expression.
Collapse
Affiliation(s)
- Pieter De Bleser
- Bioinformatics Core, VIB, B-9052 Ghent, Belgium
- Department for Molecular Biomedical Research, VIB, B-9052 Ghent, Belgium
- Department of Molecular Biology, Ghent University, B-9052 Ghent, Belgium
| | - Bart Hooghe
- Bioinformatics Core, VIB, B-9052 Ghent, Belgium
- Department for Molecular Biomedical Research, VIB, B-9052 Ghent, Belgium
- Department of Molecular Biology, Ghent University, B-9052 Ghent, Belgium
| | - Dominique Vlieghe
- Bioinformatics Core, VIB, B-9052 Ghent, Belgium
- Department for Molecular Biomedical Research, VIB, B-9052 Ghent, Belgium
- Department of Molecular Biology, Ghent University, B-9052 Ghent, Belgium
| | - Frans van Roy
- Department for Molecular Biomedical Research, VIB, B-9052 Ghent, Belgium
- Department of Molecular Biology, Ghent University, B-9052 Ghent, Belgium
| |
Collapse
|